---
title: "Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) in HIV-1 infection: Dosing and administration questions"
description: "Dosing and administration questions on Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) in HIV-1 infection, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Dosing, Taking treatment, and Before treatment. Questions: What is the Biktarvy dosage for adults and children? Does Biktarvy need to be taken with food? What tests are needed before starting Biktarvy? Can Biktarvy be started before baseline lab results are back? 4 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/dosing-and-administration"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) in HIV-1 infection: Dosing and administration questions

Manufacturer: Gilead Sciences, Inc.  
Prescribing information: [Biktarvy](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf)

## Dosing

<a id="biktarvy-dose"></a>

### What is the Biktarvy dosage for adults and children?

> “Dosage: Adult and pediatric patients weighing ≥25 kg: 1 tablet containing 50 mg bictegravir (BIC), 200 mg emtricitabine (FTC), and 25 mg tenofovir alafenamide (TAF) taken once daily with or without food. Pediatric patients weighing ≥14 kg to <25 kg: 1 tablet containing 30 mg BIC, 120 mg FTC, and 15 mg TAF taken once daily with or without food. For these pediatric patients, who are unable to swallow a whole tablet, the tablet can be split and each part taken separately as long as all parts are ingested within approximately 10 minutes.”

Source: [BIKTARVY: Important Safety Information, captured 2026-11-12](https://www.biktarvyhcp.com/important-safety-information#:~:text=Dosage%3A%20Adult%20and%20pediatric%20patients,ingested%20within%20approximately%2010%20minutes.)

## Taking treatment

<a id="biktarvy-food"></a>

### Does Biktarvy need to be taken with food?

> “Take BIKTARVY 1 time each day with or without food.”

Source: [BIKTARVY: Prescribing information, page 46, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=46)

> “Pharmacokinetic Properties of the Components of BIKTARVY  
>
> Bictegravir (BIC) 
> Emtricitabine (FTC) 
> Tenofovir 
> Alafenamide (TAF)”

Source: [BIKTARVY: Prescribing information, page 22, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=22)

> “Effect of high-fat 
> meal 
> (relative to fasting)<sup>b</sup> 
> AUC 
> ratio 
> 1.24 (1.16, 1.33) 
> 0.96 (0.93, 0.99) 
> 1.63 (1.43, 1.85) 
>
> Cmax 
> ratio 
>  1.13 (1.06, 1.20) 
> 0.86 (0.78, 0.93) 
> 0.92 (0.73, 1.14)”

Source: [BIKTARVY: Prescribing information, page 22, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=22)

> “b.  Values refer to geometric mean ratio [high-fat meal/ fasting] in PK parameters and (90% confidence interval). High 
> fat meal is approximately 800  kcal, 50% fat.”

Source: [BIKTARVY: Prescribing information, page 22, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=22)

Note: Each row of Table 4 lists values in header order: bictegravir (BIC), emtricitabine (FTC), then tenofovir alafenamide (TAF).

## Before treatment

<a id="biktarvy-testing-before-start"></a>

### What tests are needed before starting Biktarvy?

> “Testing with BIKTARVY according to the Prescribing Information<sup>2</sup>
>
> Prior to or when initiating BIKTARVY, and during treatment, assess serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all patients as clinically appropriate. In patients with chronic kidney disease, assess serum phosphorus.
>
> Prior to or when initiating BIKTARVY, test for HBV infection.
>
> Prescribing Information contains no HLA-B*5701 testing requirement.”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/about-biktarvy/early-treatment#:~:text=Testing%20with%20BIKTARVY%20according%20to,contains%20no%20HLA%2DB%2A5701%20testing%20requirement.)

<a id="biktarvy-rapid-start"></a>

### Can Biktarvy be started before baseline lab results are back?

> “According to the DHHS guidelines, BIKTARVY can be started immediately in your appropriate patients<sup>1</sup>
>
> The following tests should be performed at treatment initiation; however, you do not have to wait for the results before starting your patients on BIKTARVY, except for in individuals with a history of long-acting cabotegravir as
> pre-exposure prophylaxis, where genotype testing done before the start of ART should include screening for integrase strand transfer inhibitor (INSTI)-resistance mutations. Because of the long half-life of CAB-LA, persistent drug exposure at levels suboptimal to prevent infection may select for INSTI-resistant virus.<sup>1</sup>
>
> Resistance testing
>
> HBV testing
>
> CD4 testing
>
> Viral load testing
>
> Once test results are received, the treatment regimen can be modified if needed<sup>1</sup>”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/about-biktarvy/early-treatment#:~:text=According%20to%20the%20DHHS%20guidelines%2C,regimen%20can%20be%20modified%20if)

> “BIKTARVY is not indicated for patients with known or suspected substitutions associated with resistance to bictegravir or tenofovir.<sup>2</sup>”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/about-biktarvy/early-treatment#:~:text=BIKTARVY%20is%20not%20indicated%20for,with%20resistance%20to%20bictegravir%20or)

## Related pages
- [Medical information: Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide): HIV-1 infection](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection)
- [Indication](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/safety)
- [Specific populations](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/drug-interactions)
- [Storage and supply](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/guidelines)
